Press coverage about Vanda Pharmaceuticals (NASDAQ:VNDA) has trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vanda Pharmaceuticals earned a news impact score of 0.02 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.5204215672242 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Vanda Pharmaceuticals Inc. (VNDA) Downgraded by Zacks Investment Research to Sell (americanbankingnews.com)
- Oppenheimer Holdings Weighs in on Vanda Pharmaceuticals Inc.’s Q3 2018 Earnings (VNDA) (americanbankingnews.com)
- Brokerages Anticipate Vanda Pharmaceuticals Inc. (VNDA) Will Announce Quarterly Sales of $44.40 Million (americanbankingnews.com)
- Vanda Pharmaceuticals Announces Participation at the … – PR Newswire (press release) (prnewswire.com)
- Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : October 10, 2017 (finance.yahoo.com)
Shares of Vanda Pharmaceuticals (VNDA) traded up 0.62% during trading on Thursday, hitting $16.35. 102,200 shares of the company were exchanged. The firm’s market capitalization is $733.43 million. The firm’s 50-day moving average price is $17.46 and its 200 day moving average price is $15.62. Vanda Pharmaceuticals has a 12 month low of $12.70 and a 12 month high of $18.99.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.18. The company had revenue of $42.06 million during the quarter, compared to analyst estimates of $40.31 million. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The firm’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.01 EPS. On average, equities research analysts expect that Vanda Pharmaceuticals will post ($0.43) earnings per share for the current fiscal year.
VNDA has been the subject of a number of analyst reports. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 18th. Jefferies Group LLC reissued a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research note on Tuesday, August 29th. Piper Jaffray Companies increased their price objective on shares of Vanda Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a research note on Thursday, September 14th. BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 22nd. Finally, Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research note on Thursday, September 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $21.29.
ILLEGAL ACTIVITY WARNING: “Vanda Pharmaceuticals (VNDA) Given Media Sentiment Rating of 0.02” was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.com-unik.info/2017/10/12/vanda-pharmaceuticals-vnda-given-media-sentiment-rating-of-0-02.html.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
What are top analysts saying about Vanda Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vanda Pharmaceuticals Inc. and related companies.